We evaluated the efficacy of equine infectious anaemia virus (EIAV)-based lentiviral vectors encoding endostatin (EIA-V.endostatin) or angiostatin (EIAV.angiostatin) in inhibiting angiogenesis and vascular hyperpermeability in the laserinduced model of choroidal neovascularisation (CNV). Equine infectious anaemia virus.endostatin, EIAV.angiostatin or control (EIAV.null) vectors were administered into the subretinal space of C57Bl/6J mice. Two weeks after laser injury CNV areas and the degree of vascular hyperpermeability were measured by image analysis of in vivo fluorescein angiograms. Compared with EIAV.null-injected eyes, EIAV.endostatin resulted in a 59.5% ( Po0.001) reduction in CNV area and a reduction in hyperpermeability of 25.6% ( Po0.05). Equine infectious anaemia virus.angiostatin resulted in a 50.0% ( Po0.05) reduction in CNV area and a 23.9% ( Po0.05) reduction in hyperpermeability.
Introduction
Choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) remains the leading cause of irreversible, severe visual loss in patients aged over 60 years in developed countries. 1, 2 Established treatments for CNV, including laser photocoagulation and photodynamic therapy, are effective only in specific subgroups of patients. 1, 3 These treatments are ablative in nature, result in only modest slowing of disease progression, have a significant incidence of recurrences and typically require repeated administration as they do not directly address the underlying pro-angiogenic stimuli. [3] [4] [5] An improved understanding of the molecular mechanisms involved in angiogenesis is currently facilitating the development of novel biological and pharmacological therapies designed to arrest progression or induce regression of neovascularisation by redressing the imbalance between angiogenic and angiostatic stimuli. Intraocular delivery is an attractive route of administration for such therapies since it is likely to minimise potential systemic adverse effects of antiangiogenic agents that may be particularly relevant to the elderly population already at risk of vascular disease. Emerging pharmacological therapies include an aptamer directed against the 165 isoform of vascular endothelial growth factor (VEGF) 6 and an anti-VEGF monoclonal antibody fragment, 7 both of which are reported to result in a reduction of severe visual loss following intravitreal administration in patients. 6, 8, 9 Since the half-life of these agents in the vitreous is brief, 10, 11 repeated injections are required to maintain therapeutic levels in the eye and prevent CNV recurrence. Repeated intravitreal injections present a cumulative risk of ocular complications including retinal detachment, vitreous haemorrhage, endophthalmitis and cataract, 6 and have significant financial implications. Gene-based strategies, in contrast, offer the means to achieve the local sustained delivery of a therapeutic protein following a single procedure to introduce an appropriate vector to an intraocular site. Lentivirus-based vectors are attractive candidates for the delivery of therapeutic transgenes targeting CNV since they stably mediate high levels of transgene expression in the retina. [12] [13] [14] Following delivery to the subretinal space, lentiviral vectors typically efficiently transduce the retinal pigment epithelium (RPE), 12, 13 a monolayer of cells that is intimately involved both anatomically and pathologically in choroidal neovascularisation, and is therefore ideally suited to the local delivery of therapeutic proteins in this context. Equine infectious anaemia virus (EIAV) is a non-primate lentivirus that causes a persistent non-fatal infection in horses, donkeys and mules, 15 but is non-pathogenic in humans. 16 We have recently demonstrated that subretinal delivery of EIAV-based vectors in mice mediates rapid onset, highly efficient and sustained reporter gene expression (up to 16 months) in the retina, predominantly in RPE cells with variable expression in photoreceptor cells. 14 Endostatin and angiostatin are potent endogenous angiostatic cytokines that have been extensively evaluated for their antitumourigenic properties. 17, 18 Endostatin is an internal fragment of collagen XVIII and was first isolated from the conditioned media of a murine haemangioendothelioma cell line. Although its precise mechanisms of action are not well defined, its tumour suppressive properties are in part attributed to inhibition of tumour-associated angiogenesis. 18 Endostatin downregulates the expression of the antiapoptotic proteins Bcl-2 and Bcl-X L 19 and may interact with low-affinity glypican or high-affinity-specific endothelial cell surface receptors 20 and the integrins a v and a 5 , 21 promoting apoptosis and inhibiting migration specifically of endothelial cells involved in active neovascularisation and not those forming mature vasculature. 19, 22 Suppression of endothelial cell activity may also result from downregulation of VEGF expression, 23, 24 or direct inhibition of VEGF receptors (flt-1 and kdr), 25 this mechanism partly explaining endostatin-mediated inhibition of VEGFinduced retinal neovascularisation. 26 Angiostatin is a cleavage product (containing the kringle domains) of plasminogen and was first isolated from a subclone of human Lewis lung carcinoma cells. 17 Similar to endostatin, angiostatin promotes the apoptosis of proliferating vascular endothelial cell populations. [27] [28] [29] [30] This effect may be mediated by increasing the tyrosine kinase activity of focal adhesion kinase. 30 In addition, angiostatin inhibits migration and proliferation by binding to the a and b subunits of ATP synthase on the surface of endothelial cells. 31 Binding to tissue plasminogen activator prevents plasminogen activation and also reduces cellular migration and invasion. 32 Additional mechanisms may involve increasing selectin, 28 RhoA 33 and caveolin-1 activity, 34 inhibition of ERK activity 35 and downregulation of VEGF expression. 24, 36 Initial visual loss due to CNV is typically the result of serous exudation and haemorrhage from the hyperpermeable vessels of the neovascular complex, leading to local disruption of retinal architecture and loss of function.
Since vascular hyperpermeability appears central to vision loss in CNV, this feature presents a further opportunity for therapeutic intervention in addition to the process of angiogenesis itself. As sustained delivery of angiostatic proteins may be necessary to maintain long-term efficacy in exudative AMD, it is vital that the long-term delivery of these proteins does not promote cell death or adversely affect the physiological retinal vasculature.
In this study, we generated minimal EIAV vectors, based on those used in our previous long-term expression study, 14 encoding either endostatin or angiostatin. We demonstrate that these vectors can dramatically reduce the extent of experimental CNV with no evidence of long-term deleterious effects on normal retinal vasculature, architecture or on the frequency of programmed retinal cell death. We also demonstrate that EIAV-mediated expression of either endostatin or angiostatin results in attenuation of vascular hyperpermeability in addition to their effect on the anatomical extent of CNV. To do this, we utilised a novel technique to calculate CNV-associated vascular hyperpermeability by quantifying dye leakage during in vivo fluorescein angiography. Furthermore, we examined whether these angiostatic cytokines augment the frequency of apoptosis within the CNV complexes, a mechanism that may contribute to their therapeutic efficacy.
Results

In vitro characterisation of equine infectious anaemia virus vectors
The genetic configurations of the minimal EIAV vectors used in this study are shown diagrammatically in Figure  1a . Western blot analysis of supernatants from canine osteosarcoma (D17) cells 6 days after transduction with EIAV.endostatin (Figure 1b) or EIAV.angiostatin ( Figure  1c ) confirmed the expression and secretion of endostatin and angiostatin, respectively. Recombinant human angiostatin (MW 50 kDa) was used as a positive control since a murine recombinant angiostatin (MW 43 kDa) was not readily available. Neither endostatin nor angiostatin were detected in supernatants of cells transduced with EIAV.null (Figure 1b and c) .
Expression of endostatin or angiostatin in vivo
To confirm transgene expression from the EIAV.endostatin and EIAV.angiostatin vectors in vivo, a nested reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on total RNA isolated from vector-treated eyes. In vivo endostatin and angiostatin expression was demonstrated in eyes receiving EIAV.endostatin and EIAV. angiostatin, respectively, and neither transgene was detected in untreated eyes (Figure 1d ). No gene amplification product could be detected in any eyes in the absence of reverse transcriptase, indicating the absence of contaminating endostatin or angiostatin DNA (data not shown).
Equine infectious anaemia virus-mediated upregulation of endostatin or angiostatin inhibits laser-induced choroidal neovascularisation
We first compared the mean area of laser-induced CNV lesions following subretinal delivery of EIAV.endostatin, EIAV.angiostatin or EIAV.null with the area of lesions in the untreated contralateral control eyes (Figure 2a , c, e and g and Figure 3 ). Delivery of EIAV.endostatin resulted in a 40.4% mean reduction in CNV area compared with internal uninjected controls (39557473 pixels vs 66427583 pixels; Po0.001). Delivery of EIAV.angiostatin resulted in a 31.0% reduction in area of CNV membranes compared with uninjected control eyes (48717422 vs 70627536 pixels; Po0.001). The mean area of induced CNV lesions following delivery of EIAV.null was 56.9% greater than in uninjected eyes (973871127 vs 62087820 pixels; P ¼ 0.02). The mean CNV area was comparable in all three uninjected groups. Analysis of variance EIAV delivery of angiostatic genes inhibits CNV KS Balaggan et al demonstrated that EIAV-mediated delivery of endostatin or angiostatin resulted in statistically significant decreases in CNV area compared with EIAV.null-injected controls (Kruskal-Wallis test; Po0.001) and no significant difference in angiostatic efficacy between these two thera- 181-190). Mechanisms may include inhibiting endothelial cell proliferation, survival, migration and invasion, or promoting the apoptosis of proliferating endothelial cells. We examined whether these angiostatic cytokines promoted apoptosis within laser-induced CNV complexes, a mechanism that could potentially have contributed to the therapeutic efficacy observed in this study. Mice received subretinal injections of the EIAV vectors or phosphate-buffered saline (PBS) 14 days after laser-induced Bruch's membrane rupture. Injections were targeted to ensure that each induced CNV was exposed to the injected suspension or solution. Eyes were retrieved 10 days after vector delivery to take into account the kinetics of transgene expression after subretinal delivery of EIAV vectors, 14 and to allow sufficient time for the expressed proteins to exert any pro-apoptotic effects on the induced CNV. Cryosections (Figures 5a-f) were stained for apoptotic cells using an in situ TdT-dUTP terminal nick end labeling (TUNEL) assay, and for vascular endothelium using fluorescein isothiocyanate (FITC)-conjugated Griffonia simplicifolia I isolectin B4 (FITC-GSL I-IB4). Delivery of EIAV.endostatin or EIAV.angiostatin resulted in a significantly greater percentage of cells within the CNV complexes to undergo apoptotic cell death (20.771.9%; Po0.001 and 11.371.5%; Po0.05, respectively), as compared with uninjected control eyes (4.771.0%) (Figure 5g ). However, of the two groups treated by injection of a therapeutic vector, there was only a significantly greater percentage of apoptotic cells in the EIAV.endostatin group compared with the EIAV.null-injected (6.571.5%; Po0.01) or PBSinjected (7.771.5%; Po0.01) control groups. The difference between the EIAV.endostatin and EIAV.angiostatin groups was also significant (Po0.05). In all injected and uninjected eyes, TUNEL-positive neurosensory retinal cells were also present and were localised to areas immediately overlying the induced CNV (Figures 5a-e) . No TUNEL staining was observed in negative control eyes (Figure 5f ).
Equine infectious anaemia virus-mediated expression of endostatin or angiostatin does not promote apoptotic cell death in non-lasered eyes
It is highly desirable that strategies targeting angiogenesis have minimal long-term negative consequences on cells other than the proliferating endothelial cells forming the CNV complexes. We sought to examine whether gene delivery of endostatin or angiostatin promoted apoptosis in neurosensory retinal cells, physiological retinal or choroidal vascular endothelium, or in other ocular cells. TdT-dUTP terminal nick end labeling assays were performed on cryosections from orientated, non-lasered eyes 5 weeks after receiving subretinal injections of either of the EIAV vectors (Figure 6a-c) . Some eyes received subretinal PBS or served as uninjected controls (not shown). There were no significant differences in the mean number of apoptotic cells per section in each eye in the EIAV.endostatin (17.375.9) or EIAV.angiostatin (16.977.1) groups compared with either the EIAV.null-injected (31.9710.2), PBS-injected (16.072.6) or uninjected (2.1570.53) eyes (Figure 6d ). There were, however, a significantly greater number of apoptotic cells in eyes receiving EIAV.null or PBS compared with uninjected eyes.
In all injected eyes, nearly all apoptotic cells were localised to the neurosensory retina immediately overlying the injection tracts in each eye, rather than being evenly distributed throughout the injected retina ( Figure  6a ). Morphologically, the vast majority of apoptotic cells were photoreceptors but also included other neurosensory retinal cells, RPE cells and cells within the choroid and sclera. However, there were no significant differences between either of the EIAV groups and the PBS group, which controls for any procedure-related alterations in apoptosis frequency. No TUNEL staining was observed in the mature retinal capillaries (Figure 6b In order to investigate the possibility of long-term consequences on physiological retinal vasculature due either to vector-related toxicity or to sustained expression of the therapeutic transgene, we examined highresolution images of FITC-dextran-perfused retinal flatmounts prepared from normal animals 12 months following subretinal administration of EIAV vectors ( Figure 7 ). Qualitative examination demonstrated normal retinal vascular perfusion in each of the superficial, connecting and deep retinal vascular beds with no evidence of capillary non-perfusion. Histological analysis of eyes from animals at the 12-month time point was performed, which revealed no evidence of deleterious effects on retinal morphology (Figure 7 ).
Discussion
In this study, we describe the first therapeutic application of EIAV lentiviral vectors in an ocular disease model. Delivery of either EIAV.endostatin or EIAV.angiostatin resulted in significant and comparable inhibition of both angiogenesis and vascular hyperpermeability in laser-EIAV delivery of angiostatic genes inhibits CNV KS Balaggan et al EIAV delivery of angiostatic genes inhibits CNV KS Balaggan et al induced CNV. The results using EIAV.endostatin are similar to a previous study using intravenously delivered recombinant adenoviral (rAd) vectors expressing endostatin which resulted in a 53% reduction in CNV area compared with null vector controls. 37 Recombinant adeno-associated vectors (rAAV) delivering endostatin inhibit experimental retinopathy of prematurity. 38 Overexpression of endostatin using rAd and bovine immunodeficiency vectors also inhibits retinal neovascularisation, vasopermeability and retinal detachment in transgenic mice overexpressing VEGF in photoreceptors. 26 The effect of EIAV.angiostatin in the present study compares favourably with a previous report in which rAAV vectors delivering angiostatin resulted in 28% inhibition of laser-induced CNV formation in rats. 39 It is not, however, possible to directly compare our results in terms of efficacy with those from these previous studies using rAd or rAAV vectors, as these studies have utilised different models, animal species, or analysis methods.
Unexpectedly, subretinal delivery of EIAV.null vectors resulted in a significant increase in the extent of subsequent CNV formation compared with uninjected controls. Although we cannot exclude the possibility that this effect is specific to the injected vector, we believe it more likely to be a result of retinal detachment induced to expose outer retinal tissues to vector suspension. In all injected eyes, laser burns were applied exclusively to previously injected areas with the aim of inducing CNV in the immediate vicinity of transgene expression. It is possible that the creation of a retinal detachment may disrupt the interphotoreceptor matrix (IPM) and reduce RPE-photoreceptor adhesion that would thereby facilitate the extension of CNV subsequently induced in that area. This hypothesis is supported by studies demonstrating regional changes in IPM composition and RPE/neurosensory retinal adhesion as a result of sham subretinal injection, 40, 41 and our observation that artefactual retinal detachment during histological processing is more common in previously subretinally injected eyes than in uninjected eyes, even when retrieved many months after injection. The effects of sham subretinal injections observed in this and other studies 42, 43 may reflect differences in the extent of the retinal area detached for exposure to injected suspensions and the relative positions of the detached areas to the sites of induced CNV. If, therefore, the induction of a retinal detachment for vector delivery facilitates growth of CNV within the subretinal space then the angiostatic efficacy of an expressed protein in experimental studies may be underestimated. In situations where the therapeutic 
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protein is secreted and sufficiently diffusible, an effective therapeutic effect may be achieved by the targeted transduction of an area of retina some distance from the CNV lesion, to avoid involving the area of CNV directly in the induced detachment. With a view to potential clinical application, there may be an advantage in restricting the area of subretinal vector delivery to the immediate site of subretinal neovascularisation, which is often associated with a small pre-existing area of serous retinal elevation resulting from exudation. We were interested to determine whether local expression of either endostatin or angiostatin could mediate a useful therapeutic effect by reducing hyperpermeability of the CNV complex in addition to its anatomical extent. Assessing leakage of fluorescein dye on angiography is a highly clinically relevant method of assessing the vascular permeability of CNV complexes, and is often used as an end point in clinical trials of potential treatments for CNV. Although this leakage can be graded subjectively, we developed an objective system that allows for the quantification of CNV-associated dye leakage (Balaggan et al. manuscript in preparation). Using this method we have shown that local expression of either endostatin or angiostatin results in an attenuation of the vascular permeability associated with experimental CNV in addition to their potent effect on angiogenesis itself. This finding corroborates reports of similar effects in other models of ocular neovascularisation. 26, 39 Assuming retinal cell viability, a reduction in the degree of exudatation from CNV in patients would be expected to result in improved macular function.
The precise mechanisms underlying the effects of endostatin and angiostatin on angiogenesis and vascular hyperpermeability remain to be fully elucidated. Since VEGF upregulation plays a crucial role in experimental laser-induced CNV formation, 44, 45 endostatin-mediated VEGF receptor antagonism, 25 or endostatin-or angiostatin-mediated VEGF downregulation 23, 24, 36 may be important mechanisms contributing to the angiostatic effects observed in our study. Additional mechanisms may involve stabilisation or upregulation of endothelial cell adhesion complexes 46, 47 that are important for the maintenance of retinal vascular integrity. 48 Another pathway that may potentially be influenced by endostatin or angiostatin involves the selective induction of apoptosis in proliferating vascular endothelial cells. 19, 22, [27] [28] [29] [30] We were interested to determine whether this was a mechanism that might have contributed to the angiostasis we observed in our study. While there were a greater number of apoptotic cells within CNV in eyes receiving EIAV.endostatin as compared with injected controls, this was not the case in eyes receiving EIAV.angiostatin. These results suggest that endostatin may exert its angiostatic effects at least in part by this mechanism, although its other mechanisms are also likely to be important. The demonstration of significant angiostatic and antipermeability efficacy following treatment with EIAV.angiostatin suggests that angiostatininduced inhibition of endothelial proliferation, migration and invasion, may provide a relatively greater contribution to angiostasis in this model than its pro-apoptotic activity. Although there was a difference in the level of apoptosis induced by EIAV.endostatin and EIAV.angiostatin, there was no significant difference between these two vectors in overall efficacy.
Angiostatic agents inhibiting the proliferation, migration, invasion or permeability of vascular endothelium can inhibit the development and leakage from new CNV when given prophylactically, and may potentially inhibit the extension, recurrence and leakage from established CNV, a situation that more closely resembles the clinical disease. However, significant apoptotic activity may confer the capacity to achieve the exciting but challenging therapeutic goal of inducing the regression of established CNV, which may translate into additional improvements in macular function in patients. The efficacies of the vectors tested in this study in inducing regression of established experimental CNV are yet to be evaluated.
For all long-term strategies targeting ocular neovascularisation, it is important to consider the possibility that vector delivery or sustained expression of an angiostatic protein may result in adverse effects, for example, promoting cell destruction in retinal or other ocular cells. We detected very small numbers of apoptotic cells in all injected, non-lasered eyes. These were highly localised to areas of retina immediately overlying the injection tract, and the overall degree of positivity in any of the three EIAV groups was no greater than that observed in the PBS-injected group, which controls for any procedure-related effects. TdT-dUTP terminal nick end labeling positivity is therefore most likely to be the result of needle-induced trauma, as opposed to being attributable to vector-or expressed protein-related toxicity, in which positivity would be expected throughout the two injected retinal hemispheres. Similarly, in lasered eyes TUNEL-positive neurosensory retinal cells were only present immediately overlying the induced CNV and were also present in uninjected eyes. This suggests that their death is a consequence of laserinduced injury and/or due to interruption of the normal metabolic exchange in the outer retina secondary to CNV formation, rather than as a consequence of any vectoror transgene expression-related toxicity. Furthermore, no apoptosis was identified in mature retinal or choroidal vessels. These findings are supported by the demonstration of normal retinal morphology and retinal vascular perfusion 12 months following vector delivery.
Together, the results reported in this study support the potential for efficacy and for the safe clinical utilisation of optimised EIAV vectors encoding endostatin or angiostatin in the long-term management of CNV in patients.
Materials and methods
Viral vector construction
The pBlast-murine endostatin and angiostatin plasmids were obtained from InVivogen (San Diego, CA, USA). The cDNAs encoding the murine endostatin and angiostatin were subcloned as SalI-NheI fragments into the same EIAV transfer vector (the pONY8.7Null from the pONY8 series), which has been described previously. 49, 50 This created EIAV.endostatin and EIAV.angiostatin, respectively, where the transgenes are under the control of the hCMV promoter in a vector that contains a 5 0 central polypurine tract element, a modified version of the Woodchuck hepatitis virus post-transcriptional regulation element 51 and a self-inactivating 3 0 long terminal repeat.
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Viral vector production
Viral vector stocks pseudotyped with vesicular stomatitis virus-G-protein were prepared by transient transfection of the human embryonic kidney 293 T-cell line as described previously. 52 The biological titres of concentrated vectors are expressed as the number of transducing units per millilitre (TU/ml). The titre was determined by transducing 293 T cells in limiting dilutions in the presence of 8 mg/ml of polybrene. After passaging the transduced cells for 10 days, total genomic DNA was extracted and real-time PCR analysis (ABI 7700;PE Applied Biosystems) was carried out to determine the number of integrated viral genomes by comparing it to a bank viral preparation of known biological titre.
The genomic (RNA) titres were 1.0 Â 10 8 , 1.3 Â 10 8 and 5.0 Â 10 8 /ml for the EIAV.endostatin, EIAV.angiostatin and EIAV.null vectors, respectively. For these groups the integrated DNA titres were 1.3 Â 10 6 TU/ml (EIAV. endostatin), 3.1 Â 10 6 TU/ml (EIAV.angiostatin) and 5 Â 10 8 TU/ml (EIAV.null).
Western blotting
Supernatants were harvested from canine osteosarcoma (D17) cells 6 days after transduction with either of the EIAV.null, EIAV.endostatin and EIAV.angiostatin vectors. For the murine angiostatin Western blot, 10 ml of D17 supernatant or 200-500 ng of recombinant human angiostatin protein (Chemicon) was loaded on to a reducing 10% tris-glycine gel and the membrane was probed with a primary rabbit polyclonal anti-human angiostatin antibody (Abcam, 2904-100) that also crossreacts with the murine forms of angiostatin. For the murine endostatin Western blot 10 ml of D17 supernatant or 200-500 ng of recombinant murine endostatin protein (Chemicon) was loaded onto a reducing 4-20% trisglycine gel and the membrane was probed with a rabbit anti-mouse endostatin antibody (1:100) (Chemicon AB1880). The goat anti-rabbit HRP antibody (DAKO) was used as the secondary antibody (1:2000).
Reverse transcriptase-polymerase chain reaction
In vivo expression of either endostatin or angiostatin was confirmed by nested RT-PCR. Whole eyes (n ¼ 4 per group) were harvested 14 days after vector delivery and frozen in RNALater (Ambion). Individual whole eyes were homogenised and total RNA was isolated via the RNeasy mini kit (Qiagen) with the inclusion of DNAase I treatment. Reverse transcription and the first round of PCR were performed according to the One-Step SuperScript III RT-PCR system (Invitrogen, Carlsbad, CA, USA) using 500 ng of total RNA. The forward primer in the first round of PCR was designed to bind to the heterologous IL2 secretory signal of the EIAV vectorderived endostatin and angiostatin sequences, thereby eliminating the possibility of detecting the endogenous transcripts. A second nested PCR reaction was set up with 5 ml of the first RT-PCR product using the PuReTaq Ready-To-Got PCR Beads (GE Healthcare). The RT-PCR amplification to detect angiostatin was performed with two oligonucleotide primers (5 0 -CAGGATGCAACTCCT GTCTTG-3 0 and 5 0 -AGCATGTGGGCTCTGAGAAT-3 0 ) to generate a 412-bp product. The second nested PCR reaction to detect angiostatin was performed with a further set of oligonucleotide primers (5 0 -TCCTGTCTT GCATTGCACTAAGTC-3 0 and 5 0 -CGGATCTGTAGTGT AGCACCAA-3 0 ) to generate a 260-bp fragment. The RT-PCR amplification to detect endostatin was performed with two oligonucleotide primers (5 0 -CAGGATGCAA CTCCTGTCTTG-3 0 and 5 0 -GCCCCAGTAGTTTCAGTT CG-3 0 ) to generate a 492-bp product. The second nested PCR reaction to detect endostatin was performed with a further set of oligonucleotide primers (5 0 -TCCTGTCTT GCATTGCACTAAGTC-3 0 ) and (5 0 -TAGCACCTCGTCC TTCAGGT-3 0 ) to generate a 284-bp fragment. The pBLASTmEndostatin and pBLASTmAngiostatin plasmids (Invivogen) were used as positive controls for the PCR reaction (10 ng plasmid/reaction). The thermal profile of the RT-PCR step consisted of a 30 min, 551C cDNA synthesis step followed by a 2 min, 941C denaturation step. This was followed by 40 cycles consisting of a 15 s denaturation at 941C, a 30 s annealing at 581C and a 30 s extension at 681C. The nested PCR was carried out for 40 cycles consisting of a 15 s denaturation at 941C, a 30 s annealing at 551C and a 30 s extension at 721C. The PCR products were separated on a 1.5% agarose gel by electrophoresis. To rule out the possibility that gene amplification could have occurred from contaminating angiostatin DNA, a PCR reaction was carried out on the total RNA samples in the absence of the reverse transcriptase.
Subretinal injections
All animals used in this study were maintained humanely with institutional approval and in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
Adult C57Bl/6J mice were anaesthetised with an intraperitoneal injection of 0.15 ml of a mixture of Domitor (1 mg/ml (medetomidine hydrochloride, Pfizer Pharmaceuticals, Kent, UK) and ketamine (100 mg/ml, Fort Dodge Animal Health, Southampton, UK) mixed with sterile water for injections in the ratio 5:3:42. The pupils of all animals were dilated using topical 1% tropicamide and 2.5% phenylephrine (Chauvin Pharmaceuticals, Essex, UK). Mice received unilateral subretinal injections of either EIAV.endostatin (n ¼ 25), EIAV.angiostatin (n ¼ 23), or a null control vector, EIAV.null (n ¼ 21). The contralateral eyes in all animals served as uninjected internal controls. Injections were performed with the aid of an operating microscope by a single surgeon (KSB). Eyes were prolapsed and the fundi visualised using a contact lens system consisting of a drop of a coupling medium solution on the cornea (Viscotears, Novartis Pharmaceuticals, Frimley, UK) covered with a glass microscope slide coverslip. The tip of a 10 mm 34-guage needle, mounted on a 5 ml Hamilton syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) was advanced under direct visualization through the superior equatorial sclera tangentially towards the posterior pole until the aperture of the needle was visible in the subretinal space. 2 ml of vector suspension was then injected to produce a superior bullous retinal detachment, thus confirming subretinal vector administration. This approach creates a self-sealing sclerotomy allowing the vector suspension to be retained in the subretinal space until it is absorbed by the RPE, usually within 48 h post-injection. This procedure was repeated in the inferior hemisphere to produce 
Laser induction of experimental choroidal neovascularisation
At 3 weeks after vector delivery a slit-lamp-mounted diode laser system (wavelength 680 nm; Keeler, UK) was used to deliver three laser burns to the retinas of each eye (laser settings: 210 mW power, 100 ms duration, 100 mm spot diameter). These settings consistently generate a subretinal gas bubble which strongly correlates with adequate laser-induced rupture of Bruch's membrane and successful induction of CNV. In injected eyes, all laser burns were delivered to areas of retina previously detached as a result of subretinal vector administration. Three laser burns were similarly applied to corresponding areas of the contralateral uninjected eye. Only eyes in which laser-induced subretinal vapourisation bubble formation occurred were included in the analysis. Eyes were also excluded if there was significant cataract or keratopathy formation which could affect laser energy delivery or angiography.
Fundus fluorescein angiography
In vivo fundus fluorescein angiography was performed 2 weeks following laser injury. Mice were anaesthetised and pupillary mydriasis achieved as before. In all, 0.2 ml of 2% fluorescein sodium in water for injections was administered by intraperitoneal injection 5 min after anaesthetic administration. A Kowa Genesis small animal fundus camera equipped with appropriate excitation and barrier filters was used to obtain fluorescein angiograms at early (90 s after fluorescein injection) and late (7 min) phases of dye transit. At the early phase, the CNV complex is clearly defined by intravascular fluorescein dye. Although there may be some extravascular leakage, at this stage it is minimal in quantity. We have determined in optimisation experiments (data not shown) that maximum dye leakage from CNV complexes is fully demonstrated at 7 min post-administration with no further increase demonstrated at even later time points (15 min). At each phase, the three induced CNV membranes in each eye were individually photographed in rapid succession (all three lesions within 15 s). The contralateral eye was then immediately photographed.
Quantification of choroidal neovascularisation area and hyperpermeability
Angiograms were digitised and converted to a 16-bit greyscale image. The numbers of pixels representing the CNV-associated hyperfluorescence were quantified using image analysis software (Image Pro Plus, Media Cybernetics, Silver Spring, MD, USA). Lesions that had coalesced were excluded from the analysis. We developed a novel method to quantify hyperpermeability of CNV complexes using in vivo fluorescein angiography (Balaggan et al. manuscript in preparation). Images were taken of the area of fluorescence during the early phase of the angiogram, in which intravascular dye clearly demonstrates the extent of the perfused complex, and of the same lesion during the late phase, in which extravasated dye is also present. We quantified the degree of vascular permeability for each lesion by calculating the proportionate increase in area of fluorescence between the early and late phases.
In situ TdT-dUTP terminal nick end labeling of non-lasered eyes Animals received double subretinal injections of EIAV vectors or PBS or were left uninjected, and were terminally anaesthetised 5 weeks later. Cardiac perfusion was performed using 10 ml of 1% paraformaldehyde, and the eyes retrieved and post-fixed for 1 h in 1% paraformaldehyde. Eyes (n ¼ 4-6 per experimental group) were orientated and frozen in optimum cutting temperature medium, sagittally sectioned at 10 mm thickness and mounted onto polysine-coated slides. Eyes were orientated such that both superior and inferior injected hemispheres were demonstrated in each cryosection. An in situ TUNEL assay was performed using an apoptosis TdT DNA fragmentation detection kit (ApopTag Red Apoptosis Detection Kit, Chemicon, CA, USA), which stains apoptotic cells red. Nuclear counterstaining (blue) was performed using Hoechst 33342 (Molecular Probes Inc., UK) diluted 1:1000 in PBS for 5 min. As positive controls, eyes were similarly retrieved and prepared from 5-week-old Rho(À/À) mice in which photoreceptors degenerate as a result of apoptotic cell death. 53 As additional positive controls, some sections were treated with DNAase I (D7291; Sigma, UK) prior to TUNEL. Briefly, sections were pre-treated with Buffer A (R001A; Promega, Madison, Wisconsin, USA) for 5 min followed by 10 min incubation at room temperature with DNAase I (1.0 mg/ml). Sections were then rinsed with five changes of dH 2 0 for 3 min each change. For negative controls, some of the DNAase-treated sections were stained using the TUNEL kit but substituting the TdT enzyme incubation step with incubation with equilibration buffer. Following TUNEL assay, some sections were incubated overnight at 41C with FITC-conjugated G. simplicifolia I isolectin B4 (FITC-GSL I-IB4; Vector Labs, Burlingham, CA. USA) to selectively stain vascular endothelial cells, washed with PBS (4 Â 5 min) and counterstained with Hoechst 33342 as described. For each eye, 10 cryosections taken at equal intervals throughout the eye were evaluated by fluorescence or confocal laser microscopy under high magnification, and the number of TUNEL-positive cells throughout all the retinal layers quantified in a masked fashion. Autofluorescent areas were excluded from the analysis.
Assessment of TdT-dUTP terminal nick end labeling positivity within choroidal neovascularisation complexes At 14 days after Bruch's membrane rupture, four eyes per group received subretinal injections of either EIAV.endostatin, EIAV.angiostatin, EIAV.null or PBS. In each eye, the CNV was visualised using the operating microscope and the injection sites placed such that each of the CNV would be directly exposed to vector or PBS upon injection of the suspension or solution into the subretinal space. Additional eyes were left uninjected. To allow for sufficient transgene expression, and in view of the transient nature of the CNV EIAV delivery of angiostatic genes inhibits CNV KS Balaggan et al induced in this model, eyes were retrieved 10 days postinjection, orientated and serially cryosectioned as described above. Following TUNEL assay, all sections were stained with FITC-GSL I-IB4 and counterstained with Hoechst 33342 as described. Sections were examined using fluorescence or confocal laser microscopy and areas of CNV identified, guided by the FITC-GSL I-IB4 staining. Quantification of the total number of cells forming the CNV and the number of TUNEL positive apoptotic cells was performed on sections taken evenly throughout each CNV lesion in a masked fashion. The percentage of apoptotic cells within the CNV in each section was calculated. The mean percentage of TUNEL-positive cells in each CNV was used as a single experimental value, and compared between groups using the Kruskal-Wallis and Dunn's tests.
Fluorescein isothiocyanate-dextran perfused retinal flatmount preparation
At 12 months post vector administration, some animals from each group were terminally anaesthetised by intraperitoneal injection of pentobarbitone, and cardiac perfusion was performed using 10 ml of PBS followed by 1 ml PBS containing 50 mg/ml high molecular weight fluorescein-labelled dextran (2 Â 10 6 average molecular weight, Sigma, Poole, UK). Eyes were enucleated (n ¼ 4-6 per group) and fixed in 4% paraformaldehyde for 3 h. The cornea, lens and iris were removed and the neurosensory retina dissected from the eyecup using Jeweller's forceps. The retina was cut radially into four quadrants, flat-mounted on a microscope slide and further fixed for 1 h in 4% paraformaldehyde. The retina was mounted in aqueous mounting medium (DAKO, UK) under a coverslip for examination by fluorescence microscopy at Â 40-200 magnification. Digital photographs were acquired by means of a Leica DC500 digital camera (Leica Microsystems UK, Milton Keynes, UK).
Paraffin wax histology
At 12 months post-vector administration, some animals from each group were terminally perfused with 10% formalin. Eyes (n ¼ 4 per group) were retrieved, post-fixed in 10% formalin overnight, and embedded in paraffin wax. Eyes were serially sectioned at 5 mm thickness, mounted onto polysine-coated slides, stained with haematoxylin and eosin, and examined by light microscopy.
Statistical analysis
Normality tests (Shapiro-Wilk and D'agostino and Pearson omnibus tests) demonstrated non-Gaussian distributions of the image analysis and apoptosis data. Unpaired non-parametric statistical tests (Mann-Whitney U-tests) were therefore employed to assess for significant differences (Po0.05) in CNV area or permeability between vector-injected and uninjected control groups. Non-parametric one-way analysis of variance tests (Kruskal-Wallis tests) and Dunn's post-tests were used to analyse for significant differences (Po0.05) between the therapeutic vector-injected (EIAV.endostatin and EIAV.angiostatin) and null vector-injected groups, and for significant differences between the two therapeutic vector injected groups. This test was also used to test for significant differences in apoptosis rates between the therapeutic and control groups. 
